Cue Biopharma Inc (NASDAQ:CUE)’s traded shares stood at 0.38 million during the last session, with the company’s beta value hitting 1.87. At the close of trading, the stock’s price was $1.28, to imply a decrease of -5.19% or -$0.07 in intraday trading. The CUE share’s 52-week high remains $2.58, putting it -101.56% down since that peak but still an impressive 64.84% since price per share fell to its 52-week low of $0.45. The company has a valuation of $81.09M, with an average of 0.23 million shares in intraday trading volume over the past 10 days and average of 425.91K shares over the past 3 months.
Analysts have given a consensus recommendation of Buy for Cue Biopharma Inc (CUE), translating to a mean rating of 1.00. Of 1 analyst(s) looking at the stock, 0 analyst(s) give CUE a Sell rating. 0 of those analysts rate the stock as Overweight while 0 advise Hold as 1 recommend it as a Buy. 0 analyst(s) have given it an Underweight rating. Estimates put the company’s current-quarter earnings per share at -0.14.
Cue Biopharma Inc (NASDAQ:CUE) trade information
After registering a -5.19% downside in the last session, Cue Biopharma Inc (CUE) has traded red over the past five days. The 5-day price performance for the stock is -11.72%, and -20.00% over 30 days. With these gigs, the year-to-date price performance is 17.43%. Short interest in Cue Biopharma Inc (NASDAQ:CUE) saw shorts transact 1.78 million shares and set a 1.54 days time to cover.
The extremes give us $4 and $4 for target low and target high price respectively. As such, CUE has been trading -212.5% off suggested target high and -212.5% from its likely low.
Cue Biopharma Inc (CUE) estimates and forecasts
The rating firms project that company’s revenue will grow 71.40% compared to the previous financial year.
Revenue forecast for the current quarter as set by 5 analysts is 1.7M. Meanwhile, for the current quarter, a total of 3 analyst(s) estimate revenue growth to 1.27M.Earnings reports from the last fiscal year show that sales brought in 1.82M and 1.72M respectively in the corresponding quarters. In this case, analysts estimate current quarter sales to fall -6.58% before dropping -26.17% in the following quarter.
An assessment of the company’s 5-year growth patterns shows that annual earnings grew an estimated 10.55% for the past 5-year period. While 2025 is set for a 33.69% return in earnings, projections for the next 5 years are at 27.96% annually.
CUE Dividends
Cue Biopharma Inc has its next earnings report out in March. However, it is important to take into account that this dividend yield ratio is just an indicator to only serve the purpose of guidance. Investors interested to invest in the stock should ponder company’s other fundamental and operations related aspects too.
Cue Biopharma Inc (NASDAQ:CUE)’s Major holders
Cue Biopharma Inc insiders hold 0.55% of total outstanding shares, with institutional holders owning 23.59% of the shares at 23.72% float percentage. In total, 23.59% institutions holds shares in the company, led by BLEICHROEDER LP. As of 2024-06-30, the company held over 2.86 million shares (or 5.7849% of shares), all amounting to roughly $3.55 million.
The next major institution holding the largest number of shares is SLATE PATH CAPITAL LP with 2.4 million shares, or about 4.8567% of shares outstanding. As of the market price on 2024-06-30, these shares were worth $2.98 million.
We also have Vanguard Total Stock Market Index Fund and Vanguard Extended Market Index Fund as the top two Mutual Funds with the largest holdings of the Cue Biopharma Inc (CUE) shares. Going by data provided on Sep 30, 2024 , Vanguard Total Stock Market Index Fund holds roughly 1.35 shares. This is just over 2.13% of the total shares, with a market valuation of $1.72 million. Data from the same date shows that the other fund manager holds a little less at 597.57, or 0.94% of the shares, all valued at about 0.76 million.
